RCM
ATYR

Raleigh Capital Management’s aTyr Pharma ATYR Stock Holding History

Raleigh Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$27 – 935
2023
Q1 		$27 Buy
+13
New +$28 ﹤0.01% 836
2022
Q2 		– Sell
-600
Closed -$3K – 675
2022
Q1 		$3K Buy
+600
New +$3.4K ﹤0.01% 533

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raleigh Capital Management's ATYR Position: Q2 2023 in Review

Raleigh Capital Management sold out of aTyr Pharma (ATYR) in Q2 2023, closing a stake of 13 shares — an estimated $27 sold.

Raleigh Capital Management first reported a position in ATYR in Q1 2022 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 41 funds tracked by Wall St. Rank hold ATYR as of Q2 2023.

  • Raleigh Capital Management reported no remaining aTyr Pharma position as of Q2 2023 after selling out during the quarter.
  • Raleigh Capital Management sold 13 aTyr Pharma shares in Q2 2023, an estimated $27.
  • Raleigh Capital Management first reported a position in aTyr Pharma in Q1 2022 and held it in 2 quarters.
  • Raleigh Capital Management's aTyr Pharma position peaked at $3K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2023.

Based on Raleigh Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.